Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1949257 · FYE Jun 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $3.20Day +1.59%1Y −31.0%Off 52W high −80.3%Vol (1Y) 176.2%
Daily closing price, split-adjusted to the current basis; 1.6y shown of 402 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover3.5d |
| 13F net flow (QoQ)−0.02% |
| Top-10 13F concentration100.0% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.6M |
| Earnings (TTM)-$38.3M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−38.7% |
| 1Y−31.0% |
| Since incept. (ann.)−64.5% |
Total return through 2026-07-30 · series begins 2024-12-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)176.2% |
| Ann. volatility (3Y)158.3% |
| Sharpe (1Y)0.34 |
| Sharpe (3Y)−0.06 |
| Max drawdown (1Y)−70.4% |
| Max drawdown (3Y)−83.3% |
| Beta (3Y vs SPY)1.28 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 187,406 | $805,846 | — | +0.0% |
| Stonepine Capital Management, LLC | 51.0M | $738,977 | — | +0.0% |
| HSBC HOLDINGS PLC | 61,372 | $264,513 | — | −84.0% |
| Regal Partners Ltd | 40,138 | $172,593 | — | −55.8% |
| PNC FINANCIAL SERVICES GROUP, INC. | 16,000 | $68,800 | — | +0.0% |
| UBS Group AG | 3,000 | $12,900 | — | −79.0% |
| RHUMBLINE ADVISERS | 121 | $519 | — | +1916.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for RADX.
